Could the kynurenine pathway be the key missing piece of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) complex puzzle?
Kavyani, Bahar, Lidbury, Brett A, Schloeffel, Richard et al. · Cellular and molecular life sciences : CMLS · 2022 · DOI
Quick Summary
This review explores whether problems with how your body processes an amino acid called tryptophan might explain ME/CFS symptoms. The kynurenine pathway is a biochemical process that helps your cells make energy and affects immune function and brain inflammation. The authors suggest that abnormalities in this pathway could be a missing piece in understanding why ME/CFS develops.
Why It Matters
Understanding the kynurenine pathway's role in ME/CFS could identify new biomarkers for diagnosis and point toward novel treatments, addressing a critical gap in a disease with no proven cure. For patients, this research offers hope that researchers are investigating specific biological mechanisms rather than viewing ME/CFS as purely psychological.
Observed Findings
The kynurenine pathway plays central roles in cellular energy production through NADH synthesis and in regulating immune function and neuroinflammation.
Kynurenine pathway metabolites have been associated with symptoms characteristic of ME/CFS including fatigue, cognitive impairment, and post-exertional malaise.
Previous investigations of other proposed pathologic hallmarks in ME/CFS have produced inconsistent results, suggesting alternative mechanisms warrant exploration.
Tryptophan metabolism dysregulation could affect both energy availability and immune-neuroinflammatory balance in ME/CFS.
Inferred Conclusions
The kynurenine pathway represents a plausible unifying mechanism that could explain multiple pathophysiological features of ME/CFS.
Targeting kynurenine pathway regulation may offer innovative therapeutic approaches for ME/CFS management and symptom relief.
Further investigation of KP abnormalities could provide much-needed biomarkers for diagnosis and prognosis of ME/CFS.
Remaining Questions
Are kynurenine pathway metabolites actually abnormal in ME/CFS patients compared to controls, and do specific patterns correlate with disease severity?
Which specific interventions targeting KP regulation could safely and effectively reduce ME/CFS symptoms in clinical practice?
What This Study Does Not Prove
This review does not provide new experimental data proving the kynurenine pathway is definitively abnormal in ME/CFS patients—it synthesizes existing literature and proposes a hypothesis. The studies reviewed show correlation between KP abnormalities and ME/CFS-like symptoms, but do not establish causation. Further clinical studies directly measuring KP metabolites in well-characterized ME/CFS cohorts are needed before confirming this mechanism.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
How does kynurenine pathway dysfunction interact with other proposed ME/CFS mechanisms such as viral reactivation, mitochondrial dysfunction, and autoimmunity?
Can KP biomarkers predict which patients will respond to future therapies targeting this pathway?